Bulk Pharmaceutical API Sources for BEPRIDIL HYDROCHLORIDE

Bulk Pharmaceutical API Sources for BEPRIDIL HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		B5016_SIGMA
NovoSeek		50088
NovoSeek		2351
NovoSeek		91725
MP Biomedicals		153627
MolPort		MolPort-003-666-445

Bepridil Hydrochloride API Sourcing Landscape

Last updated: February 19, 2026

This analysis identifies and characterizes bulk active pharmaceutical ingredient (API) sources for bepridil hydrochloride, a calcium channel blocker with antianginal and antiarrhythmic properties. The report focuses on geographical distribution, manufacturing capabilities, regulatory status, and key players in the API supply chain. Sourcing strategies for bepridil hydrochloride API are influenced by factors including cost, quality control, supply chain resilience, and adherence to Good Manufacturing Practices (GMP).

What Are the Primary Global Sources for Bepridil Hydrochloride API?

The global supply of bepridil hydrochloride API is concentrated in specific regions, driven by established chemical synthesis infrastructure and regulatory compliance. Asia, particularly India and China, represents the largest manufacturing base due to cost efficiencies and a mature pharmaceutical ingredient sector. European manufacturers also contribute, often focusing on higher-value, GMP-compliant production for regulated markets.

• India: A dominant player, India's API manufacturers benefit from established chemical synthesis expertise, large-scale production capabilities, and a significant cost advantage. The country's regulatory framework, while evolving, supports bulk API production for both domestic and international markets. Numerous Indian companies are integrated into the global pharmaceutical supply chain, producing intermediates and finished APIs.
• China: Similar to India, China possesses substantial chemical manufacturing capacity and is a significant global supplier of APIs. Chinese manufacturers often offer competitive pricing, though quality assurance and adherence to international regulatory standards can vary among producers. China’s regulatory oversight of pharmaceutical manufacturing has been strengthening in recent years.
• Europe: European API manufacturers, including those in Germany and Italy, are known for their stringent quality control and adherence to European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) GMP standards. While production costs may be higher, European APIs are often favored for their reliability and compliance with the most rigorous regulatory requirements.
• Other Regions: While less prominent, some API production may occur in other regions such as North America for specialized or niche requirements, but these do not represent significant bulk supply volumes for bepridil hydrochloride.

Which Manufacturing Standards and Regulatory Approvals Are Critical for Bepridil Hydrochloride API Sourcing?

Sourcing bepridil hydrochloride API requires strict adherence to international manufacturing standards and regulatory approvals to ensure product quality, safety, and efficacy. For pharmaceutical applications, compliance with Good Manufacturing Practices (GMP) is non-negotiable.

• Good Manufacturing Practices (GMP):
  • ICH Q7: This guideline from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use provides the minimum GMP requirements for the manufacturing of active pharmaceutical ingredients. Manufacturers must demonstrate robust quality management systems, process controls, documentation, and traceability.
  • FDA cGMP (21 CFR Parts 210 & 211): For products intended for the U.S. market, manufacturers must comply with the U.S. Food and Drug Administration's current Good Manufacturing Practices.
  • EMA GMP: Manufacturers supplying to the European Union must adhere to the European Medicines Agency's GMP guidelines.
• Drug Master Files (DMFs):
  • U.S. DMF: A submission to the FDA that provides detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. A Type II DMF is relevant for API manufacturers.
  • ASMF (Active Substance Master File) / CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia): European equivalents that provide similar detailed information for regulatory review in Europe. A CEP is issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and is often preferred for its streamlined regulatory acceptance within Europe.
• Pharmacopoeial Compliance:
  • USP (United States Pharmacopeia): APIs must meet the standards and testing requirements outlined in the USP monograph for bepridil hydrochloride, if one exists.
  • EP (European Pharmacopoeia): Similarly, compliance with the EP monograph is essential for the European market.
  • JP (Japanese Pharmacopoeia): For the Japanese market, adherence to JP standards is required.
• Regulatory Audits and Inspections:
  • Manufacturers should be prepared for audits by regulatory bodies (FDA, EMA) and by their pharmaceutical customers. A history of successful inspections is a strong indicator of a reliable supplier.

What Are the Key Technical Specifications and Quality Parameters for Bepridil Hydrochloride API?

The quality of bepridil hydrochloride API is determined by a stringent set of technical specifications and quality parameters. These parameters ensure the identity, purity, potency, and safety of the API.

Parameter	Typical Specification Range	Analytical Method	Significance
Assay (Potency)	98.0% - 102.0% (on dried basis)	HPLC (High-Performance Liquid Chromatography)	Ensures the correct amount of active drug substance is present.
Identification	Conforms to reference standard	IR Spectroscopy, HPLC Retention Time	Confirms the molecular structure of bepridil hydrochloride.
Related Substances/Impurities	Not more than X% (individual, total)	HPLC	Limits the presence of process impurities, degradation products, and potential genotoxic impurities. Specific impurity limits are critical.
Loss on Drying	Not more than 0.5%	Gravimetric analysis	Controls residual moisture content, which can affect stability and potency.
Residue on Ignition (Sulfated Ash)	Not more than 0.1%	Gravimetric analysis	Measures inorganic impurities.
Heavy Metals	Not more than 10 ppm	USP <231> or equivalent (e.g., ICP-MS)	Limits potentially toxic metal contaminants.
Residual Solvents	Per ICH Q3C guidelines	GC (Gas Chromatography)	Controls levels of organic volatile impurities used during synthesis.
Particle Size Distribution	Typically specified by customer	Laser Diffraction, Sieving	Affects dissolution rates and bioavailability in the final dosage form.
Chloride Content	Varies based on salt form (hydrochloride)	Titration	Confirms the correct salt form and stoichiometry.
pH of Solution	Typically 4.5 - 6.5 (for a 1% solution)	pH meter	Indicates the acidity or alkalinity of the API solution.

Note: Specific impurity limits are highly dependent on the synthetic route and regulatory filings. Detailed impurity profiles and acceptable limits are typically found in DMFs and pharmacopoeial monographs.

Who Are the Potential Manufacturers and Suppliers of Bepridil Hydrochloride API?

Identifying specific, consistently active manufacturers of bepridil hydrochloride API can be challenging due to market dynamics and proprietary supply chains. However, based on general API manufacturing capabilities and past market presence, the following types of companies are likely involved:

• Indian API Manufacturers: Companies with a strong presence in cardiovascular APIs and a broad portfolio of generics. Examples of companies that have historically been involved or have the capability include:

  • Divi's Laboratories
  • Laurus Labs
  • Aarti Drugs
  • Solara Active Pharma Sciences
  • (Note: Specific product availability changes frequently. Direct inquiry is necessary.)

• Chinese API Manufacturers: Large-scale chemical synthesis companies with significant export volumes. Identifying specific reliable partners requires thorough due diligence, including site audits and verification of regulatory compliance. Examples of companies that may have capabilities include:

  • WuXi AppTec (often contract manufacturing)
  • Hengdian Group
  • (Note: Due diligence is critical for this region.)

• European Manufacturers: Companies specializing in high-purity, cGMP-compliant APIs, often for niche or specialty markets.

  • Industria Chimica del Solvente S.p.A. (ICS) - Italy (Historically known for cardiovascular APIs)
  • (Note: European suppliers may focus on higher-value, regulated markets.)

• Contract Manufacturing Organizations (CMOs): Companies offering custom synthesis services. These CMOs can be located globally and are often engaged when proprietary routes or specific quality requirements are paramount.

Key Considerations for Supplier Identification:

1. Direct Inquiry: The most reliable method is direct contact with known API manufacturers or through specialized API sourcing platforms and distributors.
2. Regulatory Filings: Reviewing FDA and EMA databases for DMF filings or Certificates of Suitability can identify registered manufacturers.
3. Trade Shows & Conferences: Industry events like CPhI (Convention on Pharmaceutical Ingredients) are crucial for identifying and vetting suppliers.
4. Third-Party Audits: Engaging auditing firms to assess potential suppliers' quality systems and manufacturing sites.

What Are the Key Challenges and Risks in Sourcing Bepridil Hydrochloride API?

Sourcing bepridil hydrochloride API presents several challenges and risks that require careful management to ensure a stable and compliant supply chain.

• Regulatory Scrutiny: Bepridil is associated with significant safety concerns, including Torsades de Pointes. This leads to heightened regulatory scrutiny of API quality and manufacturing processes. Any deviation can result in rejected batches or import alerts.
• Supply Chain Volatility: Global events, geopolitical instability, and single-source reliance can disrupt supply chains, leading to shortages and price fluctuations. The concentration of manufacturing in a few regions exacerbates this risk.
• Quality Assurance & Consistency: Ensuring consistent API quality across different batches and suppliers is paramount. Variations in synthetic routes or manufacturing controls can lead to unpredictable impurity profiles.
• Cost Pressures vs. Quality: While cost is a significant factor, compromising on quality can lead to far greater financial and reputational damage. Balancing competitive pricing with robust quality assurance is a continuous challenge.
• Intellectual Property (IP) and Synthetic Routes: Understanding the IP landscape and the specific synthetic routes employed by manufacturers is crucial. This can influence sourcing options and potential patent challenges.
• Market Demand and Longevity: As bepridil hydrochloride is an older drug with known safety issues, its market demand may be declining or niche, potentially impacting the long-term viability of some API suppliers and their commitment to maintaining production.
• Geopolitical Risks: Reliance on APIs from specific countries can expose the supply chain to geopolitical tensions, trade disputes, or changes in export policies.

What are the critical factors to consider for a robust bepridil hydrochloride API sourcing strategy?

A robust sourcing strategy for bepridil hydrochloride API must prioritize quality, regulatory compliance, supply chain security, and cost-effectiveness.

• Supplier Qualification and Auditing: Implement a rigorous supplier qualification program that includes detailed assessments of quality management systems, manufacturing capabilities, regulatory history, and financial stability. Regular on-site audits, conducted by internal quality assurance teams or third-party auditors, are essential.
• Dual or Multi-Sourcing: Identify and qualify at least two independent, reliable API manufacturers located in different geographical regions. This mitigates the risk of single-source dependency and supply disruptions.
• Regulatory Intelligence: Stay abreast of evolving regulatory requirements from agencies like the FDA, EMA, and others relevant to the target markets. Proactively ensure that all selected suppliers maintain up-to-date regulatory filings (DMFs, ASMFs, CEPs).
• Supply Chain Risk Assessment: Conduct comprehensive risk assessments of the entire supply chain, including raw material suppliers to the API manufacturers. Identify potential bottlenecks, single points of failure, and areas of vulnerability.
• Contractual Agreements: Establish clear and comprehensive supply agreements with API manufacturers. These contracts should detail quality specifications, lead times, change control procedures, batch release criteria, intellectual property protection, and force majeure clauses.
• Quality Agreements: Implement detailed Quality Agreements that define the responsibilities of both the API manufacturer and the drug product manufacturer regarding quality control, batch testing, deviation management, and change notifications.
• Inventory Management: Maintain appropriate inventory levels to buffer against potential supply disruptions, while avoiding excessive carrying costs. This may involve safety stock strategies.
• Technical Transfer and Process Understanding: If switching suppliers or developing new synthetic routes, ensure thorough technical transfer processes and a deep understanding of the API's manufacturing process and critical parameters.
• Long-Term Supplier Relationships: Cultivate strong, collaborative relationships with key API suppliers. This can lead to better communication, preferential treatment during supply shortages, and joint problem-solving.
• Cost Analysis: While quality is paramount, conduct thorough cost analysis that includes not only the per-kilogram API price but also costs associated with quality control, regulatory compliance, auditing, transportation, and potential risks.

Key Takeaways

• The global bepridil hydrochloride API market is primarily supplied by manufacturers in India and China, with Europe contributing for regulated markets.
• Strict adherence to ICH Q7 GMP, FDA cGMP, EMA GMP, and pharmacopoeial standards is critical for API quality and regulatory acceptance.
• Key technical specifications include assay, related substances, loss on drying, and residual solvents, verified through methods like HPLC and GC.
• Supplier qualification, dual-sourcing, regulatory intelligence, and robust contractual agreements are essential for mitigating sourcing risks.
• The safety profile of bepridil hydrochloride leads to heightened regulatory scrutiny on API manufacturing.

Frequently Asked Questions

1. What is the typical lead time for obtaining bulk bepridil hydrochloride API from a qualified supplier? Lead times can vary significantly but typically range from 8 to 16 weeks from order placement to delivery, contingent on existing production schedules and supplier capacity.

2. Are there any specific regulatory challenges unique to sourcing bepridil hydrochloride API due to its safety profile? Yes, bepridil hydrochloride's association with severe cardiovascular adverse events, notably Torsades de Pointes, results in increased regulatory scrutiny regarding impurity profiles and manufacturing process controls by agencies like the FDA and EMA.

3. How can I verify the GMP compliance of a potential bepridil hydrochloride API manufacturer? Verification involves reviewing their regulatory filings (DMFs, ASMFs, CEPs), requesting audit reports, conducting independent site audits, and examining their quality management system documentation.

4. What is the difference between a Drug Master File (DMF) and a Certificate of Suitability (CEP) for bepridil hydrochloride API? A U.S. DMF is a submission to the FDA detailing API manufacturing information, while a CEP, issued by the EDQM, certifies that an API complies with the European Pharmacopoeia, facilitating its use in European marketing authorization applications.

5. Given bepridil's safety concerns, is it still actively manufactured and supplied globally? Yes, bepridil hydrochloride is still manufactured, though its use is limited due to safety concerns. It remains available for specific indications where benefits are deemed to outweigh risks and under strict medical supervision.

Citations

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH. [2] U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice, Current Good Manufacturing Practice Regulations Under the Federal Food, Drug, and Cosmetic Act. Code of Federal Regulations, Title 21, Parts 210 & 211. [3] European Medicines Agency. (2023). EU GMP: Guideline on the requirements of the production of medicinal products. [4] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. USP. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). EDQM.